This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
The effect of sorafenib on overall survival may depend on the hepatitis status of patients with advanced hepatocellular carcinoma (HCC), according to a study published in the Journal of Clinical Oncology.
Findings from the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial led to sorafenib becoming the standard of care for patients with advanced unresectable HCC.
Patients who were both hepatitis B virus (HBV) negative and hepatitis C virus (HCV) positive had a lower risk of death than patients with other viral statuses.
Among patients who were HBV negative and HCV positive, median overall survival for those treated with sorafenib was 12.6 months compared with 10.2 months for patients treated with other agents, which included brivanib, sunitinib, and linifanib.
Patients with other hepatitis statuses, such as HBV positive and HCV negative, did not have any improvement in overall survival attributable to sorafenib.